Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
- DOI
- 10.1016/s0140-6736(24)01762-8
- Published
- 2024 Dec 14
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-24-01762-8,
title = {Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.},
author = {Ferrante M and D'Haens G and Jairath V and Danese S and Chen M and Ghosh S and Hisamatsu T and Kierkus J and Siegmund B and Bragg SM and Crandall W and Durand F and Hon E and Lin Z and Lopes MU and Morris N and Protic M and Carlier H and Sands BE and VIVID Study Group},
year = {2024},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(24)01762-8},
url = {https://doi.org/10.1016/s0140-6736(24)01762-8}
}RIS
TY - JOUR TI - Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. AU - Ferrante M AU - D'Haens G AU - Jairath V AU - Danese S AU - Chen M AU - Ghosh S AU - Hisamatsu T AU - Kierkus J AU - Siegmund B AU - Bragg SM AU - Crandall W AU - Durand F AU - Hon E AU - Lin Z AU - Lopes MU AU - Morris N AU - Protic M AU - Carlier H AU - Sands BE AU - VIVID Study Group PY - 2024 JO - Lancet (London, England) DO - 10.1016/s0140-6736(24)01762-8 UR - https://doi.org/10.1016/s0140-6736(24)01762-8 ER -
APA
M, F., G, D., V, J., S, D., M, C., S, G., T, H., J, K., B, S., SM, B., W, C., F, D., E, H., Z, L., MU, L., N, M., M, P., H, C., BE, S., & Group, V. S. (2024). Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(24)01762-8
Source records
- pubmed · retrieved 2026-09-26T03:31:26.722Z